Free Trial

Barrington Research Reiterates Outperform Rating for U.S. Physical Therapy (NYSE:USPH)

U.S. Physical Therapy logo with Medical background

Barrington Research restated their outperform rating on shares of U.S. Physical Therapy (NYSE:USPH - Free Report) in a research note released on Tuesday morning,Benzinga reports. They currently have a $98.00 price target on the stock.

A number of other research firms have also weighed in on USPH. JMP Securities reissued a "market outperform" rating and set a $113.00 target price on shares of U.S. Physical Therapy in a research report on Tuesday, April 22nd. JPMorgan Chase & Co. cut their price objective on U.S. Physical Therapy from $120.00 to $110.00 and set an "overweight" rating for the company in a research report on Wednesday, March 19th. Finally, Wall Street Zen raised U.S. Physical Therapy from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $109.00.

Get Our Latest Report on USPH

U.S. Physical Therapy Stock Up 1.8%

Shares of NYSE USPH traded up $1.47 during mid-day trading on Tuesday, reaching $82.14. 158,966 shares of the company traded hands, compared to its average volume of 121,122. The company's fifty day moving average is $76.11 and its two-hundred day moving average is $79.58. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.17 and a current ratio of 1.17. U.S. Physical Therapy has a fifty-two week low of $62.77 and a fifty-two week high of $101.20. The stock has a market cap of $1.25 billion, a PE ratio of 37.68, a price-to-earnings-growth ratio of 3.98 and a beta of 1.44.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.46 by $0.02. U.S. Physical Therapy had a return on equity of 7.89% and a net margin of 4.57%. The company had revenue of $183.79 million for the quarter, compared to the consensus estimate of $176.78 million. During the same quarter last year, the company posted $0.51 earnings per share. The company's revenue for the quarter was up 18.0% compared to the same quarter last year. On average, analysts expect that U.S. Physical Therapy will post 2.67 earnings per share for the current year.

U.S. Physical Therapy Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 23rd were given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.19%. The ex-dividend date was Friday, May 23rd. U.S. Physical Therapy's dividend payout ratio is currently 82.57%.

Insiders Place Their Bets

In other U.S. Physical Therapy news, Director Nancy Ham sold 400 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $78.01, for a total value of $31,204.00. Following the completion of the transaction, the director owned 2,594 shares of the company's stock, valued at $202,357.94. This represents a 13.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of U.S. Physical Therapy

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. bought a new position in U.S. Physical Therapy in the fourth quarter worth $18,886,000. Bahl & Gaynor Inc. lifted its holdings in shares of U.S. Physical Therapy by 135.4% during the 4th quarter. Bahl & Gaynor Inc. now owns 260,125 shares of the company's stock worth $23,076,000 after acquiring an additional 149,622 shares during the period. Nuveen LLC bought a new position in shares of U.S. Physical Therapy during the 1st quarter worth about $8,702,000. Raymond James Financial Inc. acquired a new stake in shares of U.S. Physical Therapy during the 4th quarter valued at about $6,240,000. Finally, Nuveen Asset Management LLC increased its stake in U.S. Physical Therapy by 95.9% in the fourth quarter. Nuveen Asset Management LLC now owns 120,893 shares of the company's stock valued at $10,724,000 after acquiring an additional 59,190 shares during the period.

U.S. Physical Therapy Company Profile

(Get Free Report)

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Recommended Stories

Analyst Recommendations for U.S. Physical Therapy (NYSE:USPH)

Should You Invest $1,000 in U.S. Physical Therapy Right Now?

Before you consider U.S. Physical Therapy, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and U.S. Physical Therapy wasn't on the list.

While U.S. Physical Therapy currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines